Scancell gives positive update on melanoma treatment data
Biopharmaceutical company Scancell Holdings reported further encouraging results from the ongoing 'Phase 1/2' clinical trial of its melanoma treatment SCIB1, which it presented at the annual meeting of the American Society of Clinical Oncology in Chicago.
FTSE AIM All-Share
743.26
16:50 28/03/24
Pharmaceuticals & Biotechnology
21,366.25
17:14 28/03/24
Scancell Holdings
10.25p
16:55 28/03/24
The data showed that all 16 patients with resected diseases are still alive, while survival times are “very encouraging.” If a disease is resected it means part or all of the tumour has been removed.
Only five patients have had a recurrence of the disease, with all other patients disease-free for between 27 and 46 months since they entered the study.
Professor Lindy Durrant, joint chief executive officer of Scancell and Professor of Cancer Immunotherapy at Nottingham Unversity said: “The on-going positive results from this Phase 1/2 trial gives us confidence that our SCIB1 ImmunoBody has the potential to become the first non-toxic effective adjuvant treatment for resected melanoma.”